Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

NASDAQ:EVGN opened at $0.69 on Tuesday. The company has a fifty day moving average of $0.80 and a two-hundred day moving average of $0.73. Evogene has a fifty-two week low of $0.45 and a fifty-two week high of $1.44. The stock has a market capitalization of $28.24 million, a PE ratio of -1.29 and a beta of 1.49.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. The company had revenue of $0.58 million for the quarter, compared to analysts’ expectations of $1.73 million. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. During the same period in the previous year, the firm posted ($0.07) EPS.

Hedge Funds Weigh In On Evogene

A number of institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SNC raised its position in Evogene by 265.4% in the second quarter. BNP Paribas Arbitrage SNC now owns 26,700 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 19,393 shares during the period. Renaissance Technologies LLC increased its position in shares of Evogene by 31.8% during the 1st quarter. Renaissance Technologies LLC now owns 118,193 shares of the biotechnology company’s stock worth $74,000 after purchasing an additional 28,493 shares during the last quarter. Vident Investment Advisory LLC raised its holdings in Evogene by 68.5% in the 1st quarter. Vident Investment Advisory LLC now owns 83,868 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 34,082 shares during the period. Virtu Financial LLC acquired a new position in Evogene in the first quarter valued at about $48,000. Finally, Bank of America Corp DE boosted its stake in Evogene by 49.7% during the first quarter. Bank of America Corp DE now owns 204,521 shares of the biotechnology company’s stock worth $265,000 after buying an additional 67,867 shares during the period. Hedge funds and other institutional investors own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.